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ootnotes on
ritical Limb Ischemia*
ndrew J. Feiring, MD, FACC
ilwaukee, Wisconsin
n this issue of the Journal, Guzman et al. (1) investigate a
ovel approach for identifying patients at risk for amputa-
ion secondary to peripheral arterial disease. This study is
he first to use multidetector computed tomography to
uantify tibial artery calcification (TAC). The authors
dvance the hypothesis that TAC is a measure of the
everity of below the knee atherosclerotic disease much in
he same way as coronary artery calcification (CAC) reflects
he severity of coronary arteriopathy (2). In the lower
xtremities, amputations most commonly result from criti-
al limb ischemia (CLI) brought about by multilevel arterial
nvolvement. However, the common anatomic denominator
hat unites many of these patients is the severity of concomitant
ibial arterial disease. Consequently, using TAC as a measure
f the index of the severity of tibial disease is reasonable.
See page 1967
Critical limb ischemia is a manifestation of peripheral
rterial disease that severely restricts limb perfusion result-
ng in a mismatch between metabolic tissue demands and
xygen delivery. By definition, CLI is associated with the
linical constellation of chronic ischemic rest pain or ulcer-
tion in conjunction with hemodynamic evidence of re-
uced tissue perfusion (abnormal ankle pressure or great toe
ressures or transcutaneous oxygen pressure) (3,4). It is note-
orthy, although not surprising, that many physicians are
nfamiliar with the concept of CLI, since medical training
rograms place little emphasis on the diagnosis and treatment
f vascular disease. For example, neither Harrison’s, nor Cecil’s
extbooks of medicine have a single index entry for CLI (5,6).
title search for CLI in articles published in the Journal reveals
single citation (7). Based on CLI’s literary representation,
ne might assume that CLI is of little importance in the
ay-to-day practice of cardiologists or primary care physicians.
Critical limb ischemia is a silent plague whose enormity is
nderappreciated even by those who routinely treat it. Few
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.b
From Cardiac and Vascular Intervention, Columbia St-Mary’s Hospital, Milwau-
ee, Wisconsin.ealize that the number of CLI cases exceeds the number of
ew colorectal or breast cancer cases in the U.S. (3,8). The
stimated incidence of new CLI cases in Western countries
s between 500 to 1,000/million population/year, which
ranslates into 150,000 to 300,000 cases annually in the U.S.
he first year mortality and morbidity of CLI exceeds most
alignancies with a death rate of 25% and amputation rate
f 30% (3). Within 3 years, 60% of CLI patients will have
ied (3). It is surprising that despite modern medical
anagement (or the absence thereof), amputations for
ascular disease continue to increase (9).
So why should cardiologists worry about CLI? The reason is
hat most of these patients die from unrecognized and
ndertreated cardiovascular causes (3). This is not unex-
ected since CLI and coronary artery disease, carotid, and
enal vascular diseases share similar risk factors and patho-
hysiology. Yet for some inexplicable reason, most physi-
ians are indifferent when it comes to aggressively treating
isk factors in patients with vascular disease. For instance, in
he contemporary BASIL (Bypass versus Angioplasty in
evere Ischemia of the Leg) trial (a randomized trial of
ercutaneous transluminal angioplasty vs. bypass surgery for
LI), only one-third of the patients received lipid-lowering
gents and barely 50% were on any antiplatelets (10).
With these issues in mind, I read the study of Guzman
t al. (1) with anticipation. The authors measured TAC
rom knee to ankle using the well-established Agatston
AC scoring algorithm. The TAC scores were calculated
or normal control subjects, patients with claudication, and
LI. The latter 2 groups were culled from their vascular
urgery clinic. Receiver-operating characteristic analysis
ielded a TAC cutoff value 400 that resulted in a
ensitivity of 94%, specificity of 47%, and negative predic-
ive value of 98% for amputations. Multivariate analysis
emonstrated that TAC 400 was the strongest predictor
f amputation when compared with either ankle-brachial
ndex or traditional coronary risk factors. Furthermore, no
atients with TAC400 underwent amputation, whereas 1
f 5 with TAC400 were amputated. The authors conclude
hat TAC by multidetector computed tomography “may be a
seful measure to stratify patients into risk categories and guide
herapy aimed at limb preservation” (1).
Despite 20 years of investigation, the clinical utility of CAC
emains controversial (11,12). Most studies of CAC either
ddress risk stratification in the asymptomatic patient or triage
f the symptomatic patient (i.e., chest pain) who might benefit
rom coronary angiography. A recent study in asymptomatic
ubjects has convincingly demonstrated that the higher the
AC score the more strongly it was an independent predictor
f all-cause mortality (13). Unfortunately, few studies of CAC
re directly analogous to the present one. However, if we
xtrapolate and consider claudication to be equivalent to stable
ngina, CLI (rest pain or ulceration) to be equivalent to
nstable angina/myocardial infarction, and death compara-
le to amputation, then this study can reconcile the results
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Editorial Comment May 20, 2008:1975–6hat show that the rate of amputation may be a function of
he number and extent of diseased tibial vessels.
As the authors note, there is no reliable test for predicting
he risk of amputation in CLI. The question then becomes
hether TAC can be used to fill this void. Although the
ata convincingly demonstrate the relationship between a
AC 400 and amputation, the interpretation is less
ersuasive regarding its clinical utility. In this study, the
ere presence of CLI conferred a 1 in 3 risk of major
mputation, whereas a TAC cutoff of 400 predicted
mputation in 1 in 2 patients. However, it is not apparent
hat this additional knowledge would translate into a clin-
cally meaningful dividend because the converse is also true:
ne-half of the patients with TAC 400 did not undergo
mputations. Since the relationship between TAC 400
nd amputation was not linear, does this method help us
ssess the relative risk for an individual patient? Clearly, until
roven otherwise, all patients with CLI should be considered
o be at risk for amputation regardless of the TAC score.
espite this limitation, TAC may prove to be a useful tool for
uture investigations. The impressive negative predictive value
f TAC, especially among claudicants, may permit identifica-
ion of those patients at low risk for subsequent amputation,
ecause virtually no patients were amputated when the TAC
as 400. Additionally, serial measurement of TAC may
rove to be a robust epidemiologic tool when investigating the
atural history of claudication and CLI.
As demonstrated by this study, a 33% major 1-year
mputation rate in the 21st millennium is distressing. The
elayed medical awareness and subsequent poor clinical
utcomes clearly underscore the need for a reappraisal of our
ducational, diagnostic, and therapeutic approach to CLI.
he most effective first step is to have patients at risk
those with coronary risk factors) remove their shoes and
ocks once a year when they come to the office. As Yogi
erra said, “you can observe a lot by watching” (14).
dditionally, the traditional, surgically driven “conserva-
ive” algorithms for treating CLI have been successful in
onserving neither the limb nor the patient. Emerging
vidence suggests that CLI should be approached in the
ame manner as patients with unstable coronary syn-
rome (i.e., early angiographic evaluation and aggressive
ndovascular intervention). Recently, a number of smaller
tudies have suggested that this approach may yield limb
alvage rates in excess of 90% (15–17). Furthermore,
merging data suggest that aggressive modification with
ipid lowering and antiplatelet agents yields significant
linical dividends (18,19).
Albert Einstein noted that “not everything that counts
an be counted, and not everything that can be counted
ounts” (20). Is TAC worth counting? It is far too early
o tell. However, as with all compelling studies, this one
aises more questions than it answers and illuminates an
rea of clinical confusion and frustration. I am encour-
ged by the authors’ fresh approach and eagerly look
orward to further application of their methodology.eprint requests and correspondence: Dr. Andrew J. Feiring,
ardiac and Vascular Intervention, Columbia St-Mary’s Hospital,
uite 600, 2015 East Newport Avenue, Milwaukee, Wisconsin
3211. E-mail: afeiring@execpc.com.
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